Marshall Wace, LLP Exelixis, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

A detailed history of Marshall Wace, LLP transactions in Exelixis, Inc. stock. As of the latest transaction made, Marshall Wace, LLP holds 374,611 shares of EXEL stock, worth $13 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

374,611

Previous 35,644 950.98%

Holding current value

$13 Million

Previous $800,000 1115.13%

% of portfolio

0.01%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$21.96 - $27.6 $7.44 Million - $9.36 Million	338,967 Added 950.98%	374,611 $9.72 Million
Q2 2024 Aug 14, 2024	BUY	$20.34 - $23.73 $724,998 - $845,832	35,644 New	35,644 $800,000
Q3 2023 Nov 14, 2023	SELL	$19.04 - $22.74 $4.22 Million - $5.04 Million	-221,557 Reduced 92.87%	17,000 $371,000
Q2 2023 Aug 14, 2023	SELL	$18.17 - $20.48 $3.47 Million - $3.92 Million	-191,172 Reduced 44.49%	238,557 $4.56 Million
Q1 2023 May 15, 2023	BUY	$16.3 - $19.41 $922,384 - $1.1 Million	56,588 Added 15.17%	429,729 $8.34 Million
Q4 2022 Feb 14, 2023	BUY	$14.96 - $17.39 $4.29 Million - $4.98 Million	286,600 Added 331.17%	373,141 $5.99 Million
Q3 2022 Nov 14, 2022	SELL	$15.68 - $22.27 $7.47 Million - $10.6 Million	-476,602 Reduced 84.63%	86,541 $1.36 Million
Q2 2022 Aug 15, 2022	SELL	$17.44 - $23.16 $11.9 Million - $15.8 Million	-682,804 Reduced 54.8%	563,143 $11.7 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $17.5 Million - $23.3 Million	1,027,070 Added 469.25%	1,245,947 $28.2 Million
Q4 2021 Feb 14, 2022	SELL	$15.84 - $21.88 $6.34 Million - $8.76 Million	-400,318 Reduced 64.65%	218,877 $4 Million
Q3 2021 Nov 15, 2021	BUY	$16.3 - $21.14 $10.1 Million - $13.1 Million	619,195 New	619,195 $13.1 Million
Q3 2020 Nov 16, 2020	SELL	$20.67 - $26.94 $2.64 Million - $3.44 Million	-127,794 Closed	0 $0
Q2 2020 Aug 13, 2020	BUY	$16.46 - $27.42 $2.1 Million - $3.5 Million	127,794 New	127,794 $3.03 Million
Q3 2019 Nov 14, 2019	SELL	$17.68 - $22.65 $8.83 Million - $11.3 Million	-499,573 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$18.93 - $24.75 $9.34 Million - $12.2 Million	493,176 Added 7709.49%	499,573 $10.7 Million
Q1 2019 May 14, 2019	SELL	$19.6 - $24.76 $21.3 Million - $27 Million	-1,089,250 Reduced 99.42%	6,397 $152,000
Q4 2018 Feb 14, 2019	SELL	$13.65 - $21.8 $7.26 Million - $11.6 Million	-531,666 Reduced 32.67%	1,095,647 $21.6 Million
Q3 2018 Nov 14, 2018	BUY	$15.87 - $22.4 $13.5 Million - $19 Million	849,096 Added 109.11%	1,627,313 $28.8 Million
Q2 2018 Aug 14, 2018	BUY	$18.56 - $22.45 $14.4 Million - $17.5 Million	778,217 New	778,217 $16.7 Million

Others Institutions Holding EXEL

# of Institutions

500

Shares Held

244M

Call Options Held

2.54M

Put Options Held

2.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.2B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Exelixis, Inc. Transaction History